

according to a Suzuki coupling, in order to obtain the compound of formula (XXIV),

- the compound of formula (XXIV) is subjected to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compound of formula (XXV),

5 - the compound of formula (XXV) is subjected to a deprotection reaction in order to obtain the compound of formula (I) in which R_2 represents a group $-\text{CHF}_2$ or $-\text{CF}_3$ and R_1 and R_3 are as defined previously.

10 **10.** Medicament, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 7 or a pharmaceutically acceptable acid-addition or base-addition salt of this compound.

15 **11.** Compounds of formula (I) according to any one of Claims 1 to 7, as medicaments.

12. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 7, a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

20 ~~**13.** Use of a compound of formula (I) according to any one of Claims 1 to 7, for the preparation of a medicament for treating and preventing diseases necessitating a modulation of the b-FGFs.~~

25 ~~**14.** Combination of a compound according to any one of Claims 1 to 7 with one or more anticancer active principles and/or with a radiotherapy and/or with any anti-VEGF therapy.~~

30 ~~**15**~~**13.** Compound according to any one of Claims 1 to 7, for its use in the treatment and prevention of cancers, especially carcinomas with a substantial degree of vascularization such as lung, breast, prostate, pancreatic, bowel, kidney and oesophageal carcinomas, cancers that induce metastases, such as bowel cancer, liver cancer and stomach cancer, melanomas, gliomas, lymphomas and leukaemias, and also thrombopenias.

~~16. Compound according to any one of Claims 1 to 7, for its use in combination with one or more anticancer active principles and/or with a radiotherapy and/or with any anti-VEGF therapy.~~

- 5 ~~17~~14. Compound according to any one of Claims 1 to 7, for its use in the treatment and prevention of cardiovascular diseases such as atherosclerosis, post-angioplasty restenosis, diseases associated with complications arising after the insertion of endovascular prostheses and/or aorto-coronary bypasses or other vascular grafts, cardiac hypotrophy, vascular complications of diabetes such as diabetic retinopathy,
- 10 hepatic, renal and pulmonary fibroses, neuropathic pain, chronic inflammatory diseases such as rheumatoid arthritis or IBD, prostate hyperplasia, psoriasis, clear-cell acanthoma, osteoarthritis, achondroplasias (ACH), hypochondroplasias (HCH), TD (thanatophoric dysplasia), obesity, and macular degeneration, such as age-related macular degeneration (AMD).